Antiviral activity of 5'-O-carbonate-2',3'-dideoxy-3'-thiacytidine prodrugs against hepatitis B virus in HepG2 2.2.15 cells

International Journal of Antimicrobial Agents

Volumn 36, Issue 6, 2010, Pages 566-569

  Gagey, Dolores ^a   Ravetti, Soledad ^b   Castro, Eliana F ^a   Gualdesi, María Soledad ^b   Briñon, Margarita C ^b   Campos, Rodolfo H ^a   Cavallaro, Lucía V ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

3TC prodrugs; 5' O carbonate; HBV; Hepatitis B virus; HepG2 2.2.15

Indexed keywords

5' O CARBONATE 2',3' DIDEOXY 3' THIACYTIDINE; ANTIVIRUS AGENT; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STRUCTURE ANALYSIS; SUPERNATANT; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CELL LINE; CULTURE MEDIA; DEOXYCYTIDINE; DNA, VIRAL; HEPATITIS B VIRUS; HEPATOCYTES; HUMANS; LAMIVUDINE; PRODRUGS; VIRUS REPLICATION;

EID: 78249265656     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.08.012     Document Type: Article

References (12)

1. Management of hepatitis B. NIH Consensus and State-of-the-Science Statements, vol. 25. October 20-22, 2008. National Institutes of Health. http://consensus.nih.gov/2008/hepbstatement.pdf%20pdf.
2. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
3. Degertekin B., Lok A.S. Update on viral hepatitis: 2008. Curr Opin Gastroenterol 2009, 25:180-185.
4. Vlieghe P., Bihel F., Clerc T., Pannecouque C., Witvrouw M., De Clercq E., et al. New 3'-azido-3'-deoxythymidin-5'-yl O-(ω-hydroxyalkyl) carbonate prodrugs: synthesis and anti-HIV evaluation. J Med Chem 2001, 44:777-786.
5. Vlieghe P., Clerc T., Pannecouque C., Witvrouw M., De Clercq E., Salles J.P., et al. New 3'-azido-3'-deoxythymidin-5'-yl O-(4-hydroxyalkyl or -alkenyl or -alkylepoxide) carbonate prodrugs: synthesis and anti-HIV evaluation. J Med Chem 2001, 44:3014-3021.
6. De Clercq E. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem Pharmacol 2007, 73:911-922.
7. Anastasi C., Vlieghe P., Hantz O., Schorr O., Pannecouque C., Witvrouw M., et al. Are 5'-O-carbamate-2',3'-dideoxythiacytidine new anti-HIV and anti-HBV nucleoside drugs or prodrugs?. Bioorg Med Chem Lett 2003, 13:2459-2463.
8. Chimalakonda K.C., Agarwal H.K., Kumar A., Parang K., Mehvar R. Synthesis, analysis, in vitro characterization, and in vivo disposition of a lamivudine-dextran conjugate for selective antiviral delivery to the liver. Bioconjug Chem 2007, 18:2097-2108.
9. Ravetti S., Gualdesi M.S., Trinchero-Hernández J.S., Turk G., Briñon M.C. Synthesis and anti-HIV activity of novel 2',3'-dideoxy-3'-thiacytidine prodrugs. Bioorg Med Chem 2009, 17:6407-6413.
10. Ravetti S., Gualdesi S., Briñón M.C. Lipophilicity behavior parameters of 5'-carbonates of lamivudine with antiretroviral properties. J Liq Chrom Rel Technol 2008, 31:1014-1032.
11. Sells M.A., Chen M.L., Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc Natl Acad Sci U S A 1987, 84:1005-1009.
12. Korba B.E., Gerin J.L. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res 1992, 19:55-70.